Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | TTPA | P49638 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.51 |
| ▸ | ALOX5 | P09917 | 7/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9058170 | 0.86 | MAPT (0.47) | CYP4F2MAPTLMNATTPAMEN1 | |
| SCHEMBL9060281 | 0.85 | MAPT (0.49) | CYP4F2MAPTLMNATTPAMEN1 | |
| SCHEMBL27200231 | 0.83 | CYP4F2 (0.55) | CYP4F2MAPTLMNATTPAMEN1 | |
| SCHEMBL9075511 | 0.82 | NR1I2 (0.51) | CYP4F2MAPTLMNATTPAMEN1 | |
| SCHEMBL9467233 | 0.81 | ALOX5 (0.55) | CYP4F2MAPTLMNATTPAMEN1 | |
| SCHEMBL20821020 | 0.79 | CYP4F2 (0.55) | CYP4F2MAPTLMNATTPAMEN1 | |
| Iodide SCHEMBL30859423 | 0.78 | MAPT (0.58) | CYP4F2MAPTLMNATTPAMEN1 | |
| Iodide SCHEMBL27200208 | 0.78 | MAPT (0.58) | CYP4F2MAPTLMNATTPAMEN1 | |
| SCHEMBL20024669 | 0.78 | MAPT (0.65) | CYP4F2MAPTLMNATTPAMEN1 | |
| SCHEMBL2140164 | 0.78 | MAPT (0.65) | CYP4F2MAPTLMNATTPAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7691900-B2 | Tocopherol derivatives with a long hydroxylated chain, which can be used as neurotrophics | AXOGLIA THERAPEUTICS S.A. (LU) | 2010-04-06 | — | — | US | disclosed |
| EP-1664012-B1 | TOCOPHEROL DERIVATIVES WITH A LONG HYDROXYLATED CHAIN, WHICH CAN BE USED AS NEUROTROPHICS | UNIV PASTEUR (FR) | 2009-04-01 | — | — | EP | disclosed |
| US-20070105946-A1 | Tocopherol derivatives with a long hydroxylated chain, which can be used as neurotrophics | UNIVERSITE LOUIS PASTEUR (FR) | 2007-05-10 | — | — | US | disclosed |
| EP-1664012-A1 | TOCOPHEROL DERIVATIVES WITH A LONG HYDROXYLATED CHAIN, WHICH CAN BE USED AS NEUROTROPHICS | UNIVERSITE LOUIS PASTEUR (FR) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005030748-A1 | TOCOPHEROL DERIVATIVES WITH A LONG HYDROXYLATED CHAIN, WHICH CAN BE USED AS NEUROTROPHICS | UNIVERSITE LOUIS PASTEUR (FR) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105946-A1 | Tocopherol derivatives with a long hydroxylated chain, which can be used as neurotrophics | BDNF, GMFG, NGF | CYP4F2 1418/4885MAPT 1173/4885LMNA 1622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.